Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

Paul Abrams; Con Kelleher; David Staskin; Tomasz Rechberger; Richard Kay; Reynaldo Martina; Donald Newgreen; Asha Paireddy; Rob van Maanen; Arwin Ridder

doi:10.1016/j.eururo.2014.02.012

Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

European Urology ◽

10.1016/j.eururo.2014.02.012 ◽

2015 ◽

Vol 67 (3) ◽

pp. 577-588 ◽

Cited By ~ 126

Author(s):

Paul Abrams ◽

Con Kelleher ◽

David Staskin ◽

Tomasz Rechberger ◽

Richard Kay ◽

...

Keyword(s):

Overactive Bladder ◽

Combination Treatment ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

European Urology ◽

10.1016/j.eururo.2015.02.017 ◽

2015 ◽

Vol 67 (6) ◽

pp. 1189-1190

Author(s):

Francisco Cruz

Keyword(s):

Overactive Bladder ◽

Combination Treatment ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

Faculty Opinions recommendation of Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718339612.793493406 ◽

2014 ◽

Author(s):

Piotr Radziszewski ◽

Slawomir Poletajew

Keyword(s):

Overactive Bladder ◽

Combination Treatment ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

Faculty Opinions recommendation of Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718339612.793540483 ◽

2017 ◽

Author(s):

Lori Ann Birder

Keyword(s):

Overactive Bladder ◽

Combination Treatment ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

Efficacy and safety of s201086/GLPG1972, an ADAMTS-5 inhibitor, in patients with knee osteoarthritis: roccella, a 52-week, randomized, double-blind, dose-ranging phase 2 study

Osteoarthritis and Cartilage ◽

10.1016/j.joca.2021.02.348 ◽

2021 ◽

Vol 29 ◽

pp. S264

Author(s):

T.J. Schnitzer ◽

M. Pueyo ◽

H. Deckx ◽

E. van der Aar ◽

K. Bernard ◽

...

Keyword(s):

Knee Osteoarthritis ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Phase 2 Study ◽

Dose Ranging

Download Full-text

MP02-18 EFFICACY AND SAFETY OF DA8010, A NOVEL M3 ANTAGONIST, IN PATIENTS WITH OVERACTIVE BLADDER: RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY

The Journal of Urology ◽

10.1097/ju.0000000000001963.18 ◽

2021 ◽

Vol 206 (Supplement 3) ◽

Author(s):

Hee Seo Son ◽

Joon Chul Kim ◽

Hyeong Gon Kim ◽

Dong Gil Shin ◽

Kyu-Sung Lee ◽

...

Keyword(s):

Overactive Bladder ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726641973.793540485 ◽

2017 ◽

Author(s):

Lori Ann Birder

Keyword(s):

Overactive Bladder ◽

Phase Ii ◽

Combination Treatment ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Double Blind ◽

Patient Reported ◽

Dose Ranging

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734506216.793579336 ◽

2020 ◽

Author(s):

Nathalie Gaspar

Keyword(s):

Adult Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Metastatic Osteosarcoma ◽

Phase 2 Study

Download Full-text

28588 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a randomized, double-blind, vehicle-controlled phase 2 study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.213 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB47

Author(s):

Matthew Zirwas ◽

Zoe D. Draelos ◽

Janet DuBois ◽

Leon Kircik ◽

Angela Moore ◽

...

Keyword(s):

Seborrheic Dermatitis ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Phase 2 Study

Download Full-text

SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1836 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A617.2-A618

Author(s):

W. Kennedy ◽

P. Horn ◽

Z. Su ◽

K. Basu ◽

A. Herman ◽

...

Keyword(s):

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Lymphotoxin Alpha

Download Full-text

A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis

PLoS ONE ◽

10.1371/journal.pone.0232394 ◽

2020 ◽

Vol 15 (5) ◽

pp. e0232394 ◽

Cited By ~ 2

Author(s):

Arthur S. Waldbaum ◽

Jane R. Schwebke ◽

Jeremy R. A. Paull ◽

Clare F. Price ◽

Stephanie R. Edmondson ◽

...

Keyword(s):

Bacterial Vaginosis ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Dose Ranging

Download Full-text